Phase 2 N=35 Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
Locally Advanced Malignant Solid Neoplasm
Primary: Pathological Complete Response (pCR). — 67 Percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Bladder Cancer · Gastric Cancer · Non Small Cell Lung Cancer
Primary: To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. — 6; 6; 5; 20 participants
Phase 2 N=15 Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Progression Free Survival Rate (PFS) at 2 Years Post-Blood or Marrow Transplant (BMT) — 73.5 percentage of participants
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
Phase 2 N=35 De-Escalation Therapy for Human Papillomavirus Negative Disease
Human Papilloma Virus · Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck
Primary: Deep Response Rate (DRR) — 16; 19 Participants
Phase 2 N=60 Evaluating the Role of Neuroinflammation in Low Back Pain
Low Back Pain · Back Pain With Radiation · Back Pain Without Radiation
Primary: Changes in Thalamic Standardized Uptake Value Ratio (SUVR) — 1.188; 1.166; 1.189; 1.165 Standardized uptake value ratio — p=0.956
Phase 2 N=72 Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
Plasma Cell Leukemia · Plasma Cell Myeloma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=75 Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015
Phase 2 N=48 A Study to Evaluate the Safety and Tolerability of EXN407
Diabetic Macular Edema
Primary: The Primary Objective of the Study is to Evaluate the Ocular Safety and Tolerability (by Incidence of Ocular Adverse Events) of EXN407 Ophthalmic Solution in Dose…
Phase 2 N=13 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Phase 2 N=126 Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Primary: The Most Severe Motion Sickness Severity During Vehicle Travel — 3.4; 3.75 units on a scale
Phase 2 N=39 Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
Arthralgia · Breast Cancer
Primary: Absolute Change in Brief Pain Inventory (BPI) Worst Pain From Baseline to Week 15 — -2.4 units on a scale
Phase 2 N=16 Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Change in Mitochondrial Activity in Study Patients: Citrate Synthase — 40.56; 29.09; 27.41; 37.78 nmoles/min/mg protein
Phase 2 N=1,271 Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
Dengue Disease · Dengue Virus
Primary: Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT) — 326.31; 261.10; 184.85; 10.33 Titer
Phase 2 N=13 Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Non-small Cell Lung Cancer
Primary: Intracranial Objective Response Rate — 6; 0; 5; 0 Participants